Shots:

• The approval is based on a biomarker subgroup analysis of P-III PAOLA-1 study assessing Lynparza + bevacizumab vs bevacizumab alone as 1L maintenance treatment in patients with newly diagnosed advanced FIGO Stage III-IV high-grade serous/ endometrioid ovarian- fallopian tube- peritoneal cancer who had CR/PR to 1L treatment with Pt. based CT and bevacizumab
• Results: reduction in risk of disease progression or death by 67%- PFS (37.2mos. vs 17.7mos.); PFS2 (50.3mos. vs 35.3mos.)
• Following the approval- AZ will receive $25M as a regulatory milestone from MSD. The approval follows the CHMP’s positive opinion granted in Sept’2020

  Ref: AstraZeneca | Image: Business Standard